Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.
about
Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusThe role of empagliflozin in the management of type 2 diabetes by patient profile.Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
P2860
Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Empagliflozin for the treatmen ...... icacy based on Phase 3 trials.
@en
type
label
Empagliflozin for the treatmen ...... icacy based on Phase 3 trials.
@en
prefLabel
Empagliflozin for the treatmen ...... icacy based on Phase 3 trials.
@en
P2860
P356
P1433
P1476
Empagliflozin for the treatmen ...... icacy based on Phase 3 trials.
@en
P2093
George Dailey
P2860
P304
P356
10.1111/1753-0407.12278
P577
2015-05-18T00:00:00Z